Objective: Schizoaffective disorder is a complex illness for which optimal treatment is not
well established. Results of the first controlled, relapse-prevention study of paliperidone …

BACKGROUND: Poor medication adherence contributes to negative treatment response,
symptom relapse, and hospitalizations in schizophrenia. Many health plans use claims …

Specific Anti-hostility Effects of Atypical Antipsychotics i... : Harvard Review of Psychiatry Specific
Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine …

Objective: The ACCESS treatment model offers assertive community treatment (ACT)
embedded in an integrated care program to patients with severe psychotic disorders …

Background Poor adherence rates in Bipolar Disorder type I (BDI) and Schizoaffective
Disorder, bipolar type (SAD) may be high This study was aimed at comparing the clinical …

Background: Antipsychotic medications are conventionally divided into two groups: First-
generation and second-generation antipsychotics (FGAs and SGAs). There is a …

Background Aripiprazole lauroxil is an extended-release prodrug of aripiprazole for
intramuscular injection, approved for schizophrenia treatment. We developed a population …

Background Aripiprazole lauroxil (AL) is a long-acting injectable medication approved for
the treatment of schizophrenia. Current AL regimens are 441 mg, 662 mg, and 882 mg …

Objective: To evaluate the effectiveness of olanzapine versus aripiprazole in patients with
schizophrenia. Method: Patients aged 18 to 65 years with schizophrenia (diagnosed …

Insight has long been linked to both prognosis and functioning in patients with
schizophrenia; likewise, it is key to treatment adherence. This study seeks to assess the …